The US FDA has formally accepted SK Life Science Inc.’s new drug application (NDA) for cenobamate, the Korean firm's investigational antiepileptic for the treatment of partial-onset seizures in adults, paving the way for the company's goal of bringing to market an effective therapy for drug-resistant epilepsy, seen as the most pressing unmet medical need in this segment.
Cenobamate (YKP3089), discovered and developed by SK Biopharmaceuticals Co. Ltd. and SK Life Science, its US subsidiary, is also...






